Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q13618
UPID:
CUL3_HUMAN
Alternative names:
-
Alternative UPACC:
Q13618; A8K536; B8ZZC3; O75415; Q569L3; Q9UBI8; Q9UET7
Background:
Cullin-3, a core component of multiple cullin-RING-based BCR E3 ubiquitin-protein ligase complexes, plays a pivotal role in protein ubiquitination and degradation. It regulates various biological processes, including ion transport, cell cycle progression, and signal transduction, by targeting specific proteins for proteasomal degradation.
Therapeutic significance:
Cullin-3's involvement in diseases like Pseudohypoaldosteronism 2E and Neurodevelopmental disorder with or without autism or seizures highlights its potential as a therapeutic target. Understanding Cullin-3's role could pave the way for novel treatments for these conditions.